Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-09-04 Sale | 2024-09-06 4:18 pm | Editas Medicine Inc. | EDIT | O'Neill Gilmore Neil CEO | 1,555 | $3.4247 | $5,325 | 313,724 (Direct) | View |
| 2024-06-04 Sale | 2024-06-06 4:17 pm | Editas Medicine Inc. | EDIT | O'Neill Gilmore Neil CEO | 12,191 | $5.4956 | $66,997 | 315,279 (Direct) | View |
| 2024-03-05 Sale | 2024-03-05 8:00 pm | Editas Medicine Inc. | EDIT | O'Neill Gilmore Neil CEO | 77,824 | $9.4172 | $732,884 | 719,570 (Direct) | View |
| 2023-06-05 Sale | 2023-06-07 4:30 pm | Editas Medicine Inc. | EDIT | O'Neill Gilmore Neil CEO | 6,486 | $9.5032 | $61,638 | 130,169 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-06-21 Option Award | 2024-06-21 4:30 pm | N/A 2034-06-20 | Unity Biotechnology Inc. | UBX | O'Neill Gilmore Neil Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-03-02 Option Award | 2024-03-05 8:00 pm | N/A 2034-03-01 | Editas Medicine Inc. | EDIT | O'Neill Gilmore Neil CEO | 667,225 | $0 | 719,570 (Direct) | View |
| 2023-06-23 Option Award | 2023-06-26 5:12 pm | N/A 2033-06-22 | Unity Biotechnology Inc. | UBX | O'Neill Gilmore Neil Director | 6,000 | $0 | 6,000 (Direct) | View |
| 2023-03-02 Option Award | 2023-03-06 4:30 pm | N/A 2033-03-01 | Editas Medicine Inc. | EDIT | O'Neill Gilmore Neil CEO | 200,000 | $0 | 286,655 (Direct) | View |
| 2022-06-24 Option Award | 2022-06-27 6:10 pm | N/A 2032-06-23 | Unity Biotechnology Inc. | UBX | O'Neill Gilmore Neil Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2022-06-02 Option Award | 2022-06-06 4:44 pm | N/A 2032-06-01 | Editas Medicine Inc. | EDIT | O'Neill Gilmore Neil CEO | 1,036,864 | $0 | 1,036,864 (Direct) | View |
| 2022-05-26 Option Award | 2022-05-31 4:32 pm | N/A 2032-05-25 | Aptinyx Inc. | APTX | O'Neill Gilmore Neil Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2021-10-19 Option Award | 2021-10-22 4:19 pm | N/A 2031-10-18 | Aptinyx Inc. | APTX | O'Neill Gilmore Neil Director | 80,000 | $0 | 80,000 (Direct) | View |
| 2021-06-24 Option Award | 2021-06-28 5:26 pm | N/A 2031-06-23 | Unity Biotechnology Inc. | UBX | O'Neill Gilmore Neil Director | 13,425 | $0 | 13,425 (Direct) | View |
| 2021-02-28 Tax Withholding(A) | 2021-03-10 8:02 pm | N/A N/A | Sarepta Therapeutics Inc. | SRPT | O'Neill Gilmore Neil EVP, R&D & CMO | 524 | $86.97 | 28,546 (Direct) | View |
| 2021-03-03 Option Award(A) | 2021-03-10 8:02 pm | N/A N/A | Sarepta Therapeutics Inc. | SRPT | O'Neill Gilmore Neil EVP, R&D & CMO | 15,000 | $0 | 28,546 (Direct) | View |
| 2021-03-03 Option Award | 2021-03-05 8:05 pm | 2022-03-03 2031-03-03 | Sarepta Therapeutics Inc. | SRPT | O'Neill Gilmore Neil EVP, R&D & CMO | 75,000 | $0 | 89,070 (Direct) | View |
| 2020-12-10 Option Award | 2020-12-14 5:16 pm | N/A 2030-12-09 | Unity Biotechnology Inc. | UBX | O'Neill Gilmore Neil Director | 50,000 | $0 | 50,000 (Direct) | View |
Ownership | 2020-12-14 5:10 pm | N/A 2030-06-17 | Unity Biotechnology Inc. | UBX | O'Neill Gilmore Neil Director | 0 | $0 | 40,000 (Direct) | View |
| 2020-02-28 Option Award | 2020-02-28 8:02 pm | N/A 2030-02-28 | Sarepta Therapeutics Inc. | SRPT | O'Neill Gilmore Neil EVP, R&D & CMO | 44,200 | $0 | 51,570 (Direct) | View |